PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its ...
Recursion Pharmaceuticals’s stock price closed at $3.53. It is down -23.76% in the last 3 months and down -57.67% in the last 12 months. Recursion Pharmaceuticals saw 3 positive EPS revisions and 1 ...
Peyman Khales: Thank you, Kristen. Thank you to everyone for joining the call today. This morning, we announced our fourth quarter and full-year 2025 financial results. Through diligent execution, the ...
Following the transaction, Borgeson directly owns 6,429,863 shares of Recursion Pharmaceuticals. The company, while holding more cash than debt with a current ratio of 4.6, is quickly burning through ...
Business: Integer Holdings Corporation is a medical device contract development and manufacturing company. Its brands include Greatbatch Medical and Lake Region Medical. The company's Cardio & ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results